• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Clover Health to Report Second Quarter 2024 Financial Results on August 5

    7/22/24 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care
    Get the next $CLOV alert in real time by email

    FRANKLIN, Tenn., July 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it will report second quarter 2024 financial results after market close on Monday, August 5, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on August 5, 2024, to discuss Clover Health's business and financial results.

    Second Quarter 2024 Conference Call and Webcast Details:

    • What: Clover Health's Second Quarter 2024 Earnings Conference Call
    • When: Monday, August 5, 2024, at 5:00 p.m. Eastern Time
    • Dial In: To access the call via telephone please dial 800-245-3047 (for U.S. callers) or 203-518-9765 (for callers outside the U.S.) and enter the conference ID: CLOVQ224
    • Webcast: A live and archived webcast of the conference call will be accessible from the Investor Relations section of Clover Health's website at https://investors.cloverhealth.com/ for 12 months

    About Clover Health:

    Clover Health (NASDAQ:CLOV) is a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. For our members, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. For healthcare providers outside Clover Health's Medicare Advantage plan, we aim to extend the benefits of our data-driven technology platform to a wider audience via our subsidiary, Counterpart Health, and to enable enhanced patient outcomes and reduced healthcare costs on a nationwide scale. Clover Health has published data demonstrating the technology's impact on Medication Adherence, as well as the earlier identification and management of Diabetes and Chronic Kidney Disease.

    Press Contact:

    Andrew Still-Baxter

    [email protected]

    Investor Relations Contact:

    Ryan Schmidt

    [email protected]



    Primary Logo

    Get the next $CLOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLOV

    DatePrice TargetRatingAnalyst
    12/17/2024$6.00Buy
    Craig Hallum
    10/7/2024$4.00Neutral
    UBS
    2/25/2022$3.00 → $2.50Market Perform
    SVB Leerink
    2/2/2022$7.00 → $3.00Underperform → Market Perform
    Cowen & Co.
    2/2/2022$6.00Buy
    Canaccord Genuity
    1/19/2022$3.00Market Perform
    SVB Leerink
    1/10/2022$9.00 → $3.50Neutral
    Citigroup
    1/7/2022$9.00 → $3.50Neutral → Underperform
    Credit Suisse
    More analyst ratings

    $CLOV
    SEC Filings

    See more
    • SEC Form 144 filed by Clover Health Investments Corp.

      144 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      6/17/25 4:21:44 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Investments Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

      6/12/25 4:27:22 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Investments Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

      5/14/25 8:59:21 AM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO, Medicare Advantage Reynoso Jamie L. sold $58,487 worth of shares (20,450 units at $2.86), decreasing direct ownership by 0.64% to 3,196,401 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      6/18/25 5:26:15 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • General Counsel & Secretary Soares Karen covered exercise/tax liability with 6,404 shares, decreasing direct ownership by 0.51% to 1,256,032 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      6/17/25 5:29:37 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • CEO, Counterpart Health Wai Conrad covered exercise/tax liability with 98,411 shares, decreasing direct ownership by 3% to 3,138,535 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      6/17/25 5:26:06 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Garipalli Vivek bought $999,596 worth of shares (531,700 units at $1.88), increasing direct ownership by 61% to 1,409,267 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      8/13/24 4:06:53 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Director Garipalli Vivek bought $1,000,426 worth of shares (877,567 units at $1.14) (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      6/20/24 4:03:32 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Loengard Anna U bought $25,672 worth of shares (27,085 units at $0.95) (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      5/20/24 6:57:29 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Clover Health with a new price target

      Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00

      12/17/24 8:33:41 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • UBS initiated coverage on Clover Health with a new price target

      UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00

      10/7/24 7:45:42 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • SVB Leerink reiterated coverage on Clover Health Investments with a new price target

      SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously

      2/25/22 5:03:33 AM ET
      $CLOV
      Medical Specialities
      Health Care